OverviewChartNewsTraderScreen

Soc. Generale Discount Zert ATO 2.../  DE000SU1TZS0  /

EUWAX
6/6/2024  10:09:55 AM Chg.+0.15 Bid12:20:36 PM Ask12:20:36 PM Underlying Strike price Expiration date Option type
1.15EUR +15.00% 1.16
Bid Size: 10,000		 -
Ask Size: -		 Atos SE - EUR 6/28/2024 Call
GlobeNewswire 6/5 Atossa to Present at the Sidoti Small-Cap Investor Conference
GlobeNewswire 5/30 Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets
GlobeNewswire 5/28 NetLogistik Wins Partner Leadership Award from Blue Yonder
GlobeNewswire 5/28 Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...
GlobeNewswire 5/16 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire 5/15 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire 5/15 Calian Reports Record Results for the Second Quarter
GlobeNewswire 5/13 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/13 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing
GlobeNewswire 5/7 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
GlobeNewswire 4/29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire 4/15 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire 4/11 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
GlobeNewswire 4/9 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...
GlobeNewswire 4/1 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
GlobeNewswire 3/27 Calian Announces the Appointment of New President of Advanced Technologies
GlobeNewswire 3/25 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks
GlobeNewswire 3/19 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...
GlobeNewswire 3/18 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
GlobeNewswire 3/12 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...
GlobeNewswire 3/6 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...
GlobeNewswire 2/22 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
GlobeNewswire 1/16 New report reveals that 94% of global organizations have experienced email security incidents last y...
GlobeNewswire 1/9 Atossa Therapeutics Issues Letter to Shareholders
TeleTrader 1/3 Europe opens mixed with data, business in focus